Biopharmaceutical company DBV Technologies (NASDAQ: DBVT) shares have surged premarket on Monday after the company announced that its Marketing Authorisation Application for Viaskin Peanut has been validated by the European Medicines Agency (EMA).
Viaskin Peanut is a patch used to treat peanut allergies in children aged four to eleven years old.
Back in August, DBV revealed that it received a Complete Response Letter from the US Food and Drug Administration for its Biologics License Application for Viaskin Peanut.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The Complete Response Letter is used to communicate with companies that the FDA has completed its review into a drug or product application and decided against approving it for marketing in the current form.
DBV said it is in the process of talking to the FDA to discuss the next steps needed.
Following the Marketing Authorisation Application validation, an EMA committee will conduct a review and provide a recommendation to the European Commission on whether it should grant marketing authorisation.
The news has seen DBV Technologies Nasdaq-listed shares jump over 86% to $2.68 premarket after closing Friday’s session at $1.43.
Its Euronext Paris shares are currently trading 96% higher at €4.82.
PEOPLE WHO READ THIS ALSO VIEWED:
